Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 826503, 5 pages
http://dx.doi.org/10.1155/2014/826503
Review Article

Promise and Challenge: The Lens Model as a Biomarker for Early Diagnosis of Alzheimer's Disease

1Department of Neurology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China
2Department of Oncology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China

Received 28 June 2013; Revised 24 December 2013; Accepted 6 January 2014; Published 12 February 2014

Academic Editor: Tori L. Schaefer

Copyright © 2014 Tian Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Kerbage, C. H. Sadowsky, D. Jennings et al., “Alzheimer's disease diagnosis by detecting exogenous fluorescent signal of ligand bound to Beta amyloid in the lens of human eye: an exploratory study,” Frontiers in Neurology, vol. 4, article 62, 2013. View at Publisher · View at Google Scholar
  2. J. Hardy and D. J. Selkoe, “The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. C. R. Jack Jr., D. S. Knopman, W. J. Jagust et al., “Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade,” The Lancet Neurology, vol. 9, no. 1, pp. 119–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Karran, M. Mercken, and B. de Strooper, “The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics,” Nature Reviews Drug Discovery, vol. 10, no. 9, pp. 698–712, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. R. E. Tanzi and L. Bertram, “New frontiers in Alzheimer's disease genetics,” Neuron, vol. 32, no. 2, pp. 181–184, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. V. L. Villemagne, S. Burnham, P. Bourgeat et al., “Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study,” The Lancet Neurology, vol. 12, no. 4, pp. 357–367, 2013. View at Google Scholar
  7. C. R. Jack, D. S. Knopman, S. D. Weigand et al., “An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease,” Annals of Neurology, vol. 71, no. 6, pp. 765–775, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. C. R. Jack, D. S. Knopman, W. J. Jagust et al., “Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers,” The Lancet Neurology, vol. 12, no. 2, pp. 207–216, 2013. View at Google Scholar
  9. M. Hintersteiner, A. Enz, P. Frey et al., “In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe,” Nature Biotechnology, vol. 23, no. 5, pp. 577–583, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. P. M. Doraiswamy, R. A. Sperling, R. E. Coleman et al., “Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study,” Neurology, vol. 79, no. 16, pp. 1636–1644, 2012. View at Google Scholar
  11. L. Yang, D. Rieves, and C. Ganley, “Brain amyloid imaging—FDA approval of florbetapir F18 injection,” The New England Journal of Medicine, vol. 367, no. 10, pp. 885–887, 2012. View at Google Scholar
  12. M. Mitka, “PET imaging for Alzheimer disease: are its benefits worth the cost?” The Journal of the American Medical Association, vol. 309, no. 11, pp. 1099–1100, 2013. View at Google Scholar
  13. E. M. Reiman, Y. T. Quiroz, A. S. Fleisher et al., “Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study,” The Lancet Neurology, vol. 11, no. 12, pp. 1048–1056, 2012. View at Google Scholar
  14. K. Herholz and K. Ebmeier, “Clinical amyloid imaging in Alzheimer's disease,” The Lancet Neurology, vol. 10, no. 7, pp. 667–670, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. P. M. Thompson and H. V. Vinters, “Pathologic lesions in neurodegenerative diseases,” Progress in Molecular Biology and Translational Science, vol. 107, pp. 1–40, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Carrell and D. A. Lomas, “Conformational disease,” The Lancet, vol. 350, no. 9071, pp. 134–138, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. D. A. Valenti, “Alzheimer's disease: visual system review,” Optometry, vol. 81, no. 1, pp. 12–21, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. R. M. Dutescu, Q.-X. Li, J. Crowston, C. L. Masters, P. N. Baird, and J. G. Culvenor, “Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 247, no. 9, pp. 1213–1221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. L. E. Goldstein, J. A. Muffat, R. A. Cherny et al., “Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease,” The Lancet, vol. 361, no. 9365, pp. 1258–1265, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Melov, N. Wolf, D. Strozyk, S. R. Doctrow, and A. I. Bush, “Mice transgenic for Alzheimer disease β-amyloid develop lens cataracts that are rescued by antioxidant treatment,” Free Radical Biology and Medicine, vol. 38, no. 2, pp. 258–261, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. J. J. Harding, “Conformational changes in human lens proteins in cataract,” Biochemical Journal, vol. 129, no. 1, pp. 97–100, 1972. View at Google Scholar · View at Scopus
  22. A. Surguchev and A. Surguchov, “Conformational diseases: looking into the eyes,” Brain Research Bulletin, vol. 81, no. 1, pp. 12–24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Shinohara, H. White, M. L. Mulhern, and H. Maisel, “Cataract: window for systemic disorders,” Medical Hypotheses, vol. 69, no. 3, pp. 669–677, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Jun, J. A. Moncaster, C. Koutras et al., “δ-catenin is genetically and biologically associated with cortical cataract and future Alzheimer-related structural and functional brain changes,” PLoS One, vol. 7, no. 9, Article ID e43728, 2012. View at Google Scholar
  25. T. Cumurcu, F. Dorak, B. E. Cumurcu et al., “Is there any relation between pseudoexfoliation syndrome and Alzheimer's type dementia?” Seminars in Ophthalmology, vol. 28, no. 4, pp. 224–229, 2013. View at Google Scholar
  26. M. S. Kosinski-Collins and J. King, “In vitro unfolding, refolding, and polymerization of human γD crystallin, a protein involved in cataract formation,” Protein Science, vol. 12, no. 3, pp. 480–490, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. S. R. A. Hanson, A. Hasan, D. L. Smith, and J. B. Smith, “The major in vivo modifications of the human water-insoluble lens crystallins are disulfide bonds, deamidation, methionine oxidation and backbone cleavage,” Experimental Eye Research, vol. 71, no. 2, pp. 195–207, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. P. H. Frederikse and X.-O. Ren, “Lens defects and age-related fiber cell degeneration in a mouse model of increased AβPP gene dosage in down syndrome,” American Journal of Pathology, vol. 161, no. 6, pp. 1985–1990, 2002. View at Google Scholar · View at Scopus
  29. L. T. Chylack Jr., O. White, and W. H. Tung, “Classification of human senile cataractous change by the american cooperative cataract research group (CCRG) method: II. Staged simplication of cataract classification,” Investigative Ophthalmology and Visual Science, vol. 25, no. 2, pp. 166–173, 1984. View at Google Scholar · View at Scopus
  30. J. A. Moncaster, R. Pineda, R. D. Moir et al., “Alzheimer's disease amyloid-β links lens and brain pathology in down syndrome,” PLoS ONE, vol. 5, no. 5, Article ID e10659, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. R. P. da Cunha and J. B. Moreira, “Ocular findings in Down's syndrome,” American Journal of Ophthalmology, vol. 122, no. 2, pp. 236–244, 1996. View at Google Scholar · View at Scopus
  32. J. K. Teller, C. Russo, L. M. DeBusk et al., “Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome,” Nature Medicine, vol. 2, no. 1, pp. 93–95, 1996. View at Google Scholar · View at Scopus
  33. C. A. McLean, R. A. Cherny, F. W. Fraser et al., “Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease,” Annals of Neurology, vol. 46, no. 6, pp. 860–866, 1999. View at Google Scholar
  34. P. H. Frederikse, D. Garland, J. S. Zigler Jr., and J. Piatigorsky, “Oxidative stress increases production of β-amyloid precursor protein and β-amyloid (Aβ) in mammalian lenses, and Aβ has toxic effects on lens epithelial cells,” The Journal of Biological Chemistry, vol. 271, no. 17, pp. 10169–10174, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Michael, J. Rosandić, G. A. Montenegro et al., “Absence of beta-amyloid in cortical cataracts of donors with and without Alzheimer's disease,” Experimental Eye Research, vol. 106, pp. 5–13, 2013. View at Google Scholar
  36. C. Y. Ho, J. C. Troncoso, D. Knox et al., “Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients,” Brain Pathology, vol. 24, no. 1, pp. 25–32, 2013. View at Google Scholar
  37. C. R. Jack, H. J. Wiste, P. Vemuri et al., “Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease,” Brain, vol. 133, no. 11, pp. 3336–3348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Guo, J. Duggan, and M. F. Cordeiro, “Alzheimer's disease and retinal neurodegeneration,” Current Alzheimer Research, vol. 7, no. 1, pp. 3–14, 2010. View at Publisher · View at Google Scholar · View at Scopus